Compare · ALMR vs AVTR
ALMR vs AVTR
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Avantor Inc. (AVTR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and AVTR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $9.75B, about 4.3x ALMR ($2.29B).
- ALMR has been more active in the news (5 items in the past 4 weeks vs 3 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Avantor Inc.
- Price
- $32.99+0.67%
- $14.41+1.02%
- Market cap
- $2.29B
- $9.75B
- 1M return
- +35.37%
- -
- 1Y return
- +48.64%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- 2019
- News (4w)
- 5
- 3
- Recent ratings
- 5
- 25
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Latest ALMR
- SEC Form SCHEDULE 13G filed by Alamar Biosciences Inc.
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
- Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
- Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
- SEC Form 8-K filed by Alamar Biosciences Inc.
- Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
- Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
- Amendment: SEC Form SCHEDULE 13D/A filed by Alamar Biosciences Inc.
Latest AVTR
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
- SVP & Chief Accounting Officer Eck Steven W covered exercise/tax liability with 1,385 shares, decreasing direct ownership by 1% to 129,593 units (SEC Form 4) to satisfy withholding tax
- Avantor upgraded by Jefferies with a new price target
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports Second Quarter 2026 Results
- EVP, Chief Legal & Compliance Sokenu Claudius covered exercise/tax liability with 1,201 shares, decreasing direct ownership by 0.48% to 251,228 units (SEC Form 4) to cover withholding tax
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product